Northern Trust’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.2M | Buy |
535,566
+8,880
| +2% | +$200K | ﹤0.01% | 2005 |
|
|
2025
Q4 | $12.1M | Buy |
526,686
+27,454
| +5% | +$903K | ﹤0.01% | 1981 |
|
|
2025
Q3 | $15M | Buy |
499,232
+5,762
| +1% | +$173K | ﹤0.01% | 1879 |
|
|
2025
Q2 | $17.9M | Sell |
493,470
-74,919
| -13% | -$2.7M | ﹤0.01% | 1708 |
|
|
2025
Q1 | $20.6M | Buy |
568,389
+39,424
| +7% | +$1.64M | ﹤0.01% | 1613 |
|
|
2024
Q4 | $22.3M | Buy |
528,965
+55,641
| +12% | +$2.76M | ﹤0.01% | 1627 |
|
|
2024
Q3 | $26.3M | Buy |
473,324
+91,443
| +24% | +$4.66M | ﹤0.01% | 1455 |
|
|
2024
Q2 | $15.7M | Buy |
381,881
+14,258
| +4% | +$609K | ﹤0.01% | 1707 |
|
|
2024
Q1 | $17.2M | Sell |
367,623
-7,038
| -2% | -$332K | ﹤0.01% | 1687 |
|
|
2023
Q4 | $17.9M | Buy |
374,661
+52,090
| +16% | +$2.02M | ﹤0.01% | 1689 |
|
|
2023
Q3 | $11.5M | Buy |
322,571
+10,208
| +3% | +$404K | ﹤0.01% | 1900 |
|
|
2023
Q2 | $14.4M | Buy |
312,363
+7,653
| +3% | +$355K | ﹤0.01% | 1806 |
|
|
2023
Q1 | $12.2M | Buy |
304,710
+6,897
| +2% | +$296K | ﹤0.01% | 1888 |
|
|
2022
Q4 | $13.8M | Sell |
297,813
-39,183
| -12% | -$1.54M | ﹤0.01% | 1796 |
|
|
2022
Q3 | $14M | Buy |
336,996
+1,503
| +0.4% | +$77.2K | ﹤0.01% | 1740 |
|
|
2022
Q2 | $20M | Sell |
335,493
-2,203
| -0.7% | -$136K | ﹤0.01% | 1522 |
|
|
2022
Q1 | $24.5M | Sell |
337,696
-1,853
| -0.5% | -$129K | ﹤0.01% | 1532 |
|
|
2021
Q4 | $28.6M | Sell |
339,549
-3,264
| -1% | -$266K | ﹤0.01% | 1519 |
|
|
2021
Q3 | $30.9M | Sell |
342,813
-1,268
| -0.4% | -$115K | 0.01% | 1460 |
|
|
2021
Q2 | $32.8M | Sell |
344,081
-387,487
| -53% | -$40.4M | 0.01% | 1519 |
|
|
2021
Q1 | $83.3M | Sell |
731,568
-44,223
| -6% | -$6.02M | 0.02% | 757 |
|
|
2020
Q4 | $107M | Buy |
775,791
+33,536
| +5% | +$3.98M | 0.02% | 612 |
|
|
2020
Q3 | $61M | Sell |
742,255
-36,194
| -5% | -$3M | 0.01% | 787 |
|
|
2020
Q2 | $60.9M | Buy |
778,449
+57,346
| +8% | +$3.8M | 0.01% | 750 |
|
|
2020
Q1 | $32M | Buy |
721,103
+10,650
| +1% | +$553K | 0.01% | 1075 |
|
|
2019
Q4 | $30.3M | Sell |
710,453
-13,724
| -2% | -$566K | 0.01% | 1397 |
|
|
2019
Q3 | $31M | Buy |
724,177
+33,067
| +5% | +$1.8M | 0.01% | 1335 |
|
|
2019
Q2 | $43.9M | Buy |
691,110
+32,812
| +5% | +$2.09M | 0.01% | 1089 |
|
|
2019
Q1 | $45.7M | Buy |
658,298
+77,718
| +13% | +$4.44M | 0.01% | 1037 |
|
|
2018
Q4 | $25.2M | Buy |
580,580
+11,258
| +2% | +$615K | 0.01% | 1384 |
|
|
2018
Q3 | $43.5M | Buy |
569,322
+15,230
| +3% | +$1.24M | 0.01% | 1127 |
|
|
2018
Q2 | $42.6M | Buy |
554,092
+34,942
| +7% | +$2.26M | 0.01% | 1155 |
|
|
2018
Q1 | $26.5M | Buy |
519,150
+58,507
| +13% | +$2.95M | 0.01% | 1469 |
|
|
2017
Q4 | $21.4M | Sell |
460,643
-11,376
| -2% | -$558K | 0.01% | 1656 |
|
|
2017
Q3 | $25.1M | Sell |
472,019
-5,382
| -1% | -$319K | 0.01% | 1548 |
|
|
2017
Q2 | $29.7M | Buy |
477,401
+19,138
| +4% | +$1.15M | 0.01% | 1382 |
|
|
2017
Q1 | $31.1M | Buy |
458,263
+29,537
| +7% | +$2.25M | 0.01% | 1312 |
|
|
2016
Q4 | $30.1M | Buy |
428,726
+3,952
| +0.9% | +$280K | 0.01% | 1278 |
|
|
2016
Q3 | $30.1M | Sell |
424,774
-920
| -0.2% | -$58.7K | 0.01% | 1244 |
|
|
2016
Q2 | $20.8M | Sell |
425,694
-16,054
| -4% | -$1.04M | 0.01% | 1499 |
|
|
2016
Q1 | $28.6M | Buy |
441,748
+12,775
| +3% | +$836K | 0.01% | 1199 |
|
|
2015
Q4 | $48.1M | Buy |
428,973
+8,441
| +2% | +$844K | 0.02% | 824 |
|
|
2015
Q3 | $40.5M | Buy |
420,532
+274,591
| +188% | +$31.4M | 0.01% | 950 |
|
|
2015
Q2 | $14.9M | Buy |
145,941
+34,253
| +31% | +$2.66M | ﹤0.01% | 1801 |
|
|
2015
Q1 | $6.93M | Buy |
111,688
+7,596
| +7% | +$422K | ﹤0.01% | 2299 |
|
|
2014
Q4 | $4.57M | Sell |
104,092
-465
| -0.4% | -$21.3K | ﹤0.01% | 2570 |
|
|
2014
Q3 | $5.92M | Buy |
104,557
+17,746
| +20% | +$893K | ﹤0.01% | 2405 |
|
|
2014
Q2 | $3.9M | Buy |
86,811
+57,872
| +200% | +$2.38M | ﹤0.01% | 2688 |
|
|
2014
Q1 | $1.41M | Buy |
+28,939
| New | +$1.49M | ﹤0.01% | 3290 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
Northern Trust's RARE Position: Q1 2026 in Review
Northern Trust increased its Ultragenyx Pharmaceutical (RARE) stake by 1.7% in Q1 2026, buying an estimated $200K and bringing the position to 535,566 shares worth $11.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2005.
Northern Trust first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $107M in Q4 2020. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- Northern Trust held 535,566 shares of Ultragenyx Pharmaceutical worth $11.2M as of Q1 2026.
- Northern Trust bought 8,880 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $200K.
- Ultragenyx Pharmaceutical made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2005 holding.
- Northern Trust first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
- Northern Trust's Ultragenyx Pharmaceutical position peaked at $107M in Q4 2020.
- 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.